Last reviewed · How we verify
SUZ
SUZ is a CFTR potentiator that enhances the function of cystic fibrosis transmembrane conductance regulator protein to improve chloride transport in cystic fibrosis patients.
SUZ is a CFTR potentiator that enhances the function of cystic fibrosis transmembrane conductance regulator protein to improve chloride transport in cystic fibrosis patients. Used for Cystic fibrosis in patients with specific CFTR mutations responsive to potentiation.
At a glance
| Generic name | SUZ |
|---|---|
| Also known as | VX-548 |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Drug class | CFTR potentiator |
| Target | CFTR (cystic fibrosis transmembrane conductance regulator) |
| Modality | Small molecule |
| Therapeutic area | Pulmonary/Respiratory |
| Phase | FDA-approved |
Mechanism of action
SUZ works by binding to and potentiating the CFTR protein, increasing its channel-opening probability and duration, thereby enhancing chloride ion transport across epithelial cell membranes. This mechanism helps restore defective ion transport in cystic fibrosis patients, particularly those with certain CFTR mutations. The drug is designed to improve lung function and reduce disease progression in eligible CF populations.
Approved indications
- Cystic fibrosis in patients with specific CFTR mutations responsive to potentiation
Common side effects
- Headache
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants (PHASE1)
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) (PHASE3)
- A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries (PHASE4)
- A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries (PHASE4)
- Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures (PHASE4)
- RCT: Suzetrigine vs Norco for Post-op Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SUZ CI brief — competitive landscape report
- SUZ updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI